LIRAGLUTIDE CAN BE ADMINISTERED ONCE DAILY AT ANY TIME OF DAY, INDEPENDENTLY OF MEALS, AND CAN BE INJECTED SUBCUTANEOUSLY IN THE ABDOMEN, THIGH OR UPPER ARM. THE INJECTION SITE AND TIMING CAN BE CHANGED WITHOUT DOSE ADJUSTMENT.
FOR ALL PATIENTS, LIRAGLUTIDE SHOULD BE INITIATED WITH A DOSE OF 0.6 MG PER DAY FOR ONE WEEK. THE 0.6 MG DOSE IS A STARTING DOSE INTENDED TO REDUCE GASTROINTESTINAL SYMPTOMS DURING INITIAL TITRATION, AND IS NOT EFFECTIVE FOR GLYCEMIC CONTROL. AFTER ONE WEEK AT 0.6 MG PER DAY, THE DOSE SHOULD BE INCREASED TO 1.2 MG. IF THE 1.2 MG DOSE DOES NOT RESULT IN ACCEPTABLE GLYCEMIC CONTROL, THE DOSE CAN BE INCREASED TO 1.8 MG.
WHEN INITIATING LIRAGLUTIDE, CONSIDER REDUCING THE DOSE OF CONCOMITANTLY ADMINISTERED INSULIN SECRETAGOGUES (SUCH AS SULFONYLUREAS) TO REDUCE THE RISK OF HYPOGLYCEMIA